

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

NOXAFIL (all dosage forms)
(posaconazole)

Status: CVS Caremark® Criteria

Type: Initial Prior Authorization

POLICY

FDA-APPROVED INDICATIONS

Treatment of Invasive Aspergillosis

Noxafil injection and **Noxafil delayed-release tablets** are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older.

Prophylaxis of Invasive Aspergillus and Candida Infections

Noxafil is indicated for the prophylaxis of invasive *Aspergillus* and *Candida* infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows:

- **Noxafil Injection:** adults and pediatric patients 2 years of age and older
- **Noxafil delayed-release tablets:** adults and pediatric patients 2 years of age and older who weigh greater than 40 kg
- **Noxafil oral suspension:** adults and pediatric patients 13 years of age and older
- **Noxafil PowderMix for delayed-release oral suspension:** pediatric patients 2 years of age and older who weigh 40 kg or less

Treatment of Oropharyngeal Candidiasis Including Oropharyngeal Candidiasis Refractory to Itraconazole and/or Fluconazole

Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis, including oropharyngeal candidiasis refractory to itraconazole and/or fluconazole in adults and pediatric patients 13 years of age and older.

COVERAGE CRITERIA

Oropharyngeal Candidiasis

Authorization may be granted when the requested drug is being prescribed for the treatment of moderate to severe oropharyngeal candidiasis when ALL of the following criteria are met:

- The request is for Noxafil oral suspension (immediate-release)
- The patient has experienced an inadequate treatment response, intolerance or has a contraindication to fluconazole AND itraconazole oral solution

Prevention of Invasive Aspergillus and Candida Infections

Authorization may be granted when the requested drug is being prescribed for the prevention of invasive aspergillus and candida infections in a patient who is at high risk of developing these infections due to being severely immunocompromised

Treatment of Invasive Aspergillus

Noxafil PA Policy 3094-A UDR 03-2024.docx

This document contains confidential and proprietary information of CVS Caremark and cannot be reproduced, distributed or printed without written permission from CVS Caremark. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark.

©2024 CVS Health and/or its affiliates. All rights reserved. 106-58428A 021423

Authorization may be granted when the requested drug is being prescribed for the treatment of invasive aspergillosis when the following criteria is met:

- The request is for Noxafil injection or Noxafil delayed-release tablets

DURATION OF APPROVAL (DOA)

- 3094-A: DOA:
 - Prevention of invasive Aspergillus and Candida infections: 6 months
 - Treatment of invasive aspergillosis: 3 months
 - Treatment of moderate to severe oropharyngeal candidiasis: 1 month

REFERENCES

1. Noxafil [package insert]. Rahway, NJ: Merck Sharp & Dohme LLC; September 2022.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online. Waltham, MA: UpToDate, Inc.; 2024. <https://online.lexi.com>. Accessed January 12, 2024.
3. Micromedex (electronic version). Merative, Ann Arbor, Michigan, USA. Available at: <https://www.micromedexsolutions.com/> (cited: 01/12/2024).
4. Pappas P, Kauffman C, Andes D, et al. Clinical Practice Guidelines for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2016;62:1-50.